Experimental and Molecular Medicine (Aug 2023)

The deubiquitinase UCHL3 mediates p300-dependent chemokine signaling in alveolar type II cells to promote pulmonary fibrosis

  • Soo Yeon Lee,
  • Soo-Yeon Park,
  • Seung-Hyun Lee,
  • Hyunsik Kim,
  • Jae-Hwan Kwon,
  • Jung-Yoon Yoo,
  • Kyunggon Kim,
  • Moo Suk Park,
  • Chun Geun Lee,
  • Jack A. Elias,
  • Myung Hyun Sohn,
  • Hyo Sup Shim,
  • Ho-Geun Yoon

DOI
https://doi.org/10.1038/s12276-023-01066-1
Journal volume & issue
Vol. 55, no. 8
pp. 1795 – 1805

Abstract

Read online

Abstract Idiopathic pulmonary fibrosis (IPF) is a chronic, fatal, fibrotic, interstitial lung disease of unknown cause. Despite extensive studies, the underlying mechanisms of IPF development remain unknown. Here, we found that p300 was upregulated in multiple epithelial cells in lung samples from patients with IPF and mouse models of lung fibrosis. Lung fibrosis was significantly diminished by the alveolar type II (ATII) cell–specific deletion of the p300 gene. Moreover, we found that ubiquitin C-terminal hydrolase L3 (UCHL3)-mediated deubiquitination of p300 led to the transcriptional activation of the chemokines Ccl2, Ccl7, and Ccl12 through the cooperative action of p300 and C/EBPβ, which consequently promoted M2 macrophage polarization. Selective blockade of p300 activity in ATII cells resulted in the reprogramming of M2 macrophages into antifibrotic macrophages. These findings demonstrate a pivotal role for p300 in the development of lung fibrosis and suggest that p300 could serve as a promising target for IPF treatment.